A weekly regimen with dose escalation of doxorubicin for patients with advanced Hodgkin's lymphoma: results of a phase II study of the Groupe d'Etudes des Lymphomes de l'Adulte (GELA).

Abstract	This multicenter phase II study assessed the feasibility and efficacy of a weekly chemotherapy regimen with a moderately escalated dose of doxorubicin administered over 16 weeks, followed by radiation therapy (RT) to bulky sites. From July 1996 to February 1998, 44 untreated patients with stage IIIB-IV Hodgkin's lymphoma (HL), and 0 - 2 risk factors described by the Memorial Sloan-Kettering Cancer Center, were treated. Chemotherapy was a combination of increased-dose doxorubicin with conventional doses of cyclophosphamide, vinblastine, prednisone, vindesine, bleomycin, and etoposide. Patients received four cycles of the weekly regimen for 16 weeks. Forty-one patients received the planned four cycles of chemotherapy, and RT was delivered to 36 patients. The incidence of WHO grade 3 - 4 neutropenia was 90%. A total of 39 patients achieved a complete remission (88.6%). The median follow-up was 95 months. The 7-years freedom from treatment failure and overall survival estimates were 57% (95% confidence interval (CI), 41% - 70%), and 93% (95% CI, 80 - 98%), respectively. The relapse rate was related to the short duration of chemotherapy, and the failure to prevent relapses with consolidation RT. In this study population the 16-week regimen and RT to bulky sites were not sufficient for disease control.
Authors	Christophe Fermé, Pauline Brice, Anne-Sophie Michallet, Pierre Lederlin, Marine Diviné, Olivier Casasnovas, Alain Devidas, Bruno Anglaret, Dominique Cazals-Hatem, Nicolas Mounier, Groupe d'Etudes des Lymphomes de L'adulte
Journal	Leukemia & lymphoma (Leuk Lymphoma) Vol. 48 Issue 4 Pg. 691-8 (Apr 2007) ISSN: 1042-8194 [Print] United States
PMID	17454626 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
Chemical References	Antibiotics, Antineoplastic Doxorubicin
Topics	Adolescent Adult Antibiotics, Antineoplastic (administration & dosage, therapeutic use) Disease-Free Survival Doxorubicin (administration & dosage, therapeutic use) Drug Administration Schedule Female Hodgkin Disease (drug therapy) Humans Male Middle Aged Recurrence Risk Factors Time Factors Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!